Levonchiko, earlier today you posted the following.....
"Try to get a hold of yesterdays after hours upgrade by ****** and you might start adding shares with the new price target they have indicated and make sure KVN reads it.I am glad he didn't sell his Insmed shares as well.Sorry that i can't post it on line."
Could you please let us know who did the upgrade? I can't find it. I tried posting my question to this post but perhaps it is too hidden.
SNPMarketScopeViewsNews2013-10-15 10:10:13.000INSMINSMED INCORPORATEDMATTHEW MORROWINSMED (INSM) COMPLETES ARIKACE TRIAL. LEERINK SWANN REITERATES OUTPERFORM Analyst Joseph Schwartz tells salesforce encouraged by INSM announcement that enrollment of TARGET-NTM (nontuberculous mycobacterial) is complete, co.'s initial powering assumptions have been validated. Notes INSM has powered trial at 80% to demonstrate a one-step change on sevenstep bacterial density scale, but his conversations with MEDACorp KOLs (key opinion leaders), analysis of limited clinical aerozolized Amikacin data generated in refractory NTM patients and animal models
suggest Arikace's treatment effect could be much greater. Has $22 price target. M.Morrow|US;INSM|26266|US|167347. Try the suggestions below or type a new query above.
Lazard came out with a reiterate buy report (October 15) with a target of $28 (same as before). Saying that it is still one of their favorite picks and they see Arikace commercial opportunity at around $500MM ($100k per patient for 50k patients).